Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Clin Exp Med. 2023 Dec;23(8):4369-4383. doi: 10.1007/s10238-023-01120-2. Epub 2023 Jul 5.
The clinical, histological, and molecular differences between right-sided colon cancer (RCC) and left-sided colon cancer (RCC) have received considerable attention. Over the past decade, many articles have been published concerning the association between primary tumor location (PTL) of colorectal cancer and survival outcomes. Therefore, there is a growing need for an updated meta-analysis integrating the outcomes of recent studies to determine the prognostic role of right vs left-sidedness of PTL in patients with colorectal cancer. We conducted a comprehensive database review using PubMed, SCOPUS, and Cochrane library databases from February 2016 to March 2023 for prospective or retrospective studies reporting data on overall survival (OS) and cancer-specific survival (CSS) of RCC compared with LCC. A total of 60 cohort studies comprising 1,494,445 patients were included in the meta-analysis. We demonstrated that RCC is associated with a significantly increased risk of death compared with LCC by 25% (hazard ratio (HR), 1.25; 95% confidence interval (CI), 1.19-1.31; I2 = 78.4%; Z = 43.68). Results showed that patients with RCC have a worse OS compared with LCC only in advanced stages (Stage III: HR, 1.275; 95% CI 1.16-1.4; P = 0.0002; I2 = 85.8%; Stage IV: HR, 1.34; 95% CI 1.25-1.44; P < 0.0001; I2 = 69.2%) but not in primary stages (Stage I/II: HR, 1.275; 95% CI 1.16-1.4; P = 0.0002; I2 = 85.8%). Moreover, a meta-analysis of 13 studies including 812,644 patients revealed that there is no significant difference in CSS between RCC and LCC (HR, 1.121; 95% CI 0.97-1.3; P = 0.112). Findings from the present meta-analysis highlight the importance of PTL in clinical decision-making for patients with CRC, especially in advanced stages. We provide further evidence supporting the hypothesis that RCC and LCC are distinct disease entities that should be managed differently.
右侧结肠癌(RCC)和左侧结肠癌(RCC)的临床、组织学和分子差异引起了广泛关注。在过去的十年中,已经发表了许多关于结直肠癌原发肿瘤部位(PTL)与生存结果之间关联的文章。因此,需要进行一项更新的荟萃分析,综合最近研究的结果,以确定结直肠癌患者中 PTL 的右侧与左侧之间的预后作用。我们使用 PubMed、SCOPUS 和 Cochrane 图书馆数据库,从 2016 年 2 月至 2023 年 3 月,对报告右侧结肠癌与左侧结肠癌总生存(OS)和癌症特异性生存(CSS)数据的前瞻性或回顾性研究进行了全面的数据库综述。共有 60 项队列研究纳入了荟萃分析,包括 1494445 名患者。我们证明,与左侧结肠癌相比,右侧结肠癌的死亡风险增加了 25%(风险比(HR),1.25;95%置信区间(CI),1.19-1.31;I2=78.4%;Z=43.68)。结果表明,仅在晚期阶段(III 期:HR,1.275;95%CI 1.16-1.4;P=0.0002;I2=85.8%;IV 期:HR,1.34;95%CI 1.25-1.44;P<0.0001;I2=69.2%),而不是在初级阶段(I/II 期:HR,1.275;95%CI 1.16-1.4;P=0.0002;I2=85.8%),右侧结肠癌患者的 OS 比左侧结肠癌差。此外,对包括 812644 名患者的 13 项研究进行的荟萃分析显示,右侧结肠癌和左侧结肠癌的 CSS 无显著差异(HR,1.121;95%CI 0.97-1.3;P=0.112)。本荟萃分析的结果强调了 PTL 在结直肠癌患者临床决策中的重要性,特别是在晚期阶段。我们提供了进一步的证据支持右侧结肠癌和左侧结肠癌是不同疾病实体的假说,应该以不同的方式进行管理。